Haynie Law Group Pc

Services Overview

Aracari Biosciences

Increased Efficiency in Drug Discovery

Aracari’s in-house services are geared to increase the efficiency of your drug discovery pipeline by significantly enhancing the biological validity of pre-clinical testing. We can help your team de-risk pre-clinical decisions, so you can move to the next phase of your project with greater confidence. Our experienced team will work with you to custom-design a screening protocol that makes sense for your needs. Core features of our services include:

  • Efficient and accurate production of results
  • Personalized consultation to match project goals with Aracari technology
  • Confidential communication of project objectives and results

To learn more about how Aracari Biosciences' technology and services can help you accelerate your drug discovery pipeline, contact us today.

Vascular Toxicity

image2
Toxicity

Our Vascularized Micro-Organ (VMOTM) platform is ideally suited for investigating vascular toxicities. Drugs of interest flow through the vasculature at rates comparable to those seen in vivo, and metabolites, cytokines and other biomarkers released by the endothelial cells can be collected for further analysis. The platform also allows for real-time imaging of the vessel morphology. The vascular network can be fixed and stained in situ, or harvested for gene expression studies (qPCR, RNAseq, single cell RNAseq). Additionally, cytokine markers of activation can be collected upon flowing through the platform.

Permeability

Our VMOTM platform is ideally suited for studies of vascular permeability. The vascular network can be perfused with fluorophore-tagged dextrans of different molecular weight and the leak of these from the vessels in response to different stimuli can be tracked in real-time. Quantification of leak can be used to calculate permeability coefficients. In addition, drug permeability can be assessed. Larger molecules (such as Ig) can be fluorescently tagged and imaged directly. Alternatively, samples can be collected from the extravascular space and analyzed by ELISA or mass spectrometry.

Oncology

Efficacy

Our Vascularized Micro-Tumor (VMTTM) platform is ideally suited for investigating lead compound efficacy against tumors growing in a 3D, biomimetic environment. Drugs of interest are perfused through the vasculature and are delivered to the tumors, just as they are in vivo. We currently offer several different tumor models:

  • Colon Cancer
  • Breast Cancer
  • Lung Cancer
  • Pancreatic Cancer

Don’t see your tumor type of interest? Contact us to discuss your application and discuss additional tumor types currently under development.

The efficacy of both anti-tumor and anti-vascular drugs can be tested by direct measurement output of GFP-expressing tumor cells and by vascular network analysis. Cytokine markers of activation can be collected upon flowing through the platform. Additionally, tissues can be fixed and stained in situ for biomarker expression, or alternatively, tissues can be harvested for gene expression analysis (qPCR, RNAseq, single cell RNAseq).

Screening

Our VMTTM platform is configured in a higher-throughput capacity ideally suited to assess potential efficacy, toxicity, and mechanism of action for smaller libraries (i.e., 50-250 compounds) of potential anti-cancer agents. We currently offer several different tumor models:

  • Colon Cancer
  • Breast Cancer
  • Lung Cancer
  • Pancreatic Cancer

Contact us to discuss your application and discuss additional tumor types currently under development.

The efficacy of both anti-tumor and anti-vascular drugs can be tested by direct measurement output of GFP-expressing tumor cells and by vascular network analysis. Cytokine markers of activation can be collected upon flowing through the platform. Additionally, tissues can be fixed and stained in situ for biomarker expression, or alternatively, tissues can be harvested for gene expression analysis (qPCR, RNAseq, single cell RNAseq).

Immune-Oncology

Our VMTTM platform is uniquely suited to study the interactions between tumors and immune cells.  The incorporation of tumors within a network of living human vasculature enables physiologically-relevant delivery of immune cells (e.g. T Cells, monocytes, etc.) by perfusion through the blood vessels. This presents an ideal model to study immune-oncology compounds delivered into the system.  We currently offer several different tumor models:

  • Colon Cancer
  • Breast Cancer
  • Lung Cancer
  • Pancreatic Cancer

Contact us to discuss your application and discuss additional tumor types currently under development.

The anti-tumor efficacy of immune-oncology compounds can be tested by direct measurement output of GFP-expressing tumor cells. Cytokine markers of activation can be collected upon flowing through the platform. Additionally, tissues can be fixed and stained in situ for biomarker expression, or alternatively, tissues can be harvested for gene expression analysis (qPCR, RNAseq, single cell RNAseq).

Aracari Biosciences

Blood Brain Barrier

Aracari Biosciences
Permeability

Our Vascularized Micro-Brain (VMBTM) platform is ideally suited for investigating delivery of drugs across the blood-brain barrier. The vascular network can be perfused with fluorophore-tagged dextrans of different molecular weight and the leak of these from the vessels in response to different stimuli can be tracked in real-time. Quantification of leak can be used to calculate permeability coefficients. In addition, drug permeability can be assessed in a number of ways. Larger molecules (such as Ig) can be fluorescently tagged and imaged directly. Alternatively, samples can be collected from the extravascular space and analyzed by ELISA or mass spectrometry. Drugs that target BBB transporter molecules such as P-glycoprotein (e.g. Elacridar) can be used to assess whether a drug is a P-gp substrate

Platform Development

Increased Efficiency in Drug Discovery

Our platforms

  • Are built in a 96 well-plate format and compatible with plate readers, automated liquid handlers, etc.
  • Can be developed to be fully automated (gel-cell-matrix loading, interstitial flow, and perfused drug delivery)
  • Can be adjusted to match physiological scenarios of interest
  • Are optically transparent, making it compatible with a wide range of imaging modalities
  • Are customizable; we will work with clients to develop functionality unique to their needs
Aracari Biosciences

How to Get Started

Accelerate Your Testing Workflow

To learn more about ordering Kino Biosciences' technology or to find out how our solutions and services can help you, leave us your name, company, and contact information.